Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results

Oncotarget
Alberto OcañaAtanasio Pandiella

Abstract

Targeting of HER2-positive tumors with trastuzumab has shown to improve survival in early stage and advanced breast cancer. The addition of pertuzumab, another anti-HER2 antibody, to trastuzumab-containing regimens has demonstrated a modest increase in disease-free survival in the adjuvant setting. Unexpectedly, when pertuzumab was explored in combination with the antibody-drug conjugate TDM1 in the metastatic setting, no additional benefit was observed compared with dual targeting of HER2 with pertuzumab and trastuzumab, together with chemotherapy. Similar results were observed when exploring pathologic complete response in the neoadjuvant setting. In this article, we discuss basic science and translational data that may explain the limited efficacy observed with the combination of TDM1 and pertuzumab, including tumor heterogeneity, clonal selection, bystander effect or downregulation of the receptor by competitive binding. In addition, we review ongoing studies that could help to understand these findings.

References

Jan 27, 2004·Molecular Biology of the Cell·Anette M HommelgaardBo van Deurs
Sep 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Roberto GennariAlberto Costa
Mar 1, 2005·Oncogene·Giorgio ValabregaSilvia Giordano
Dec 14, 2011·The New England Journal of Medicine·José BaselgaUNKNOWN CLEOPATRA Study Group
Oct 2, 2012·The New England Journal of Medicine·Sunil VermaUNKNOWN EMILIA Study Group
Dec 4, 2014·Nature·Antonina V KurtovaKeith Syson Chan
Jun 15, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hannah DzimitrowiczRashmi Murthy
Jun 6, 2017·The New England Journal of Medicine·Gunter von MinckwitzUNKNOWN APHINITY Steering Committee and Investigators
Oct 25, 2017·British Journal of Cancer·Alexander H Staudacher, Michael P Brown
Apr 15, 2018·Cancer Research·Sara García-AlonsoAtanasio Pandiella
May 12, 2018·Cancer Treatment Reviews·Noam PondéMartine Piccart
May 31, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffMitchell Dowsett

❮ Previous
Next ❯

Citations

Apr 25, 2020·EMBO Molecular Medicine·Lucía Gandullo-SánchezAtanasio Pandiella
May 16, 2020·Journal of Cellular and Molecular Medicine·Rao Fu, Jing-Shan Tong
Mar 23, 2019·Cancers·Denis M CollinsGerhard Niederfellner
Oct 19, 2019·Breast Cancer Research : BCR·D J P van UdenC F J M Blanken-Peeters
Dec 17, 2019·British Journal of Cancer·Francis W HunterStephen M F Jamieson
Feb 24, 2020·The American Journal of Cardiology·Oscar Calvillo-ArgüellesPaaladinesh Thavendiranathan
Aug 9, 2021·Seminars in Oncology·Pei LuJennifer Y Sheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Gail D Lewis PhillipsMark X Sliwkowski
© 2022 Meta ULC. All rights reserved